Protagonist Therapeutics (PTGX) EBT (2015 - 2026)
Protagonist Therapeutics (PTGX) posted EBT of $2.3 million for Q1 2026, up 105.22% sequentially from -$43.7 million in Q4 2025, and up 119.57% YoY from $1.0 million in Q1 2025.
Protagonist Therapeutics (PTGX) EBT (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported EBT for 12 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly EBT rose 119.57% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$115.4 million (down 302.21% YoY) and the FY2025 annual result came in at -$129.3 million, down 146.29% from the prior year.
- EBT grew to $2.3 million in Q1 2026 per PTGX's latest filing, from -$43.7 million in the prior quarter.
- Over five years, EBT peaked at $210.7 million in Q1 2024 and troughed at -$66.9 million in Q1 2022.
- A 5-year average of -$6.2 million and a median of -$33.7 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT tumbled 178.95% in 2022, then surged 724.66% in 2024.
- Over 5 years, EBT stood at -$34.9 million in 2022, then jumped by 178.23% to $27.3 million in 2023, then soared by 388.88% to $133.6 million in 2024, then plunged by 132.71% to -$43.7 million in 2025, then jumped by 105.22% to $2.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered $2.3 million, -$43.7 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 165.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.11 Mn |
| Mar 31, 2026 | 2.28 Mn |
| Dec 31, 2025 | -43.72 Mn |
| Sep 30, 2025 | -39.34 Mn |
| Jun 30, 2025 | -34.60 Mn |
| Mar 31, 2025 | -11.66 Mn |
| Dec 31, 2024 | 133.64 Mn |
| Sep 30, 2024 | -33.63 Mn |
| Jun 30, 2024 | -31.29 Mn |
| Mar 31, 2024 | 210.67 Mn |
| Dec 31, 2023 | 27.34 Mn |
| Sep 30, 2023 | -34.11 Mn |
| Jun 30, 2023 | -38.46 Mn |
| Mar 31, 2023 | -33.73 Mn |
| Dec 31, 2022 | -34.94 Mn |
| Sep 30, 2022 | -33.45 Mn |
| Jun 30, 2022 | -42.66 Mn |
| Mar 31, 2022 | -66.94 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -33.80 Mn |